The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | The promise of mutant CALR-targeting therapies in MPNs
Francesco Passamonti, MD, University of Milan, Milan, Italy, comments on the potential of targeting mutated calreticulin (CALR) in myeloproliferative neoplasms (MPNs), highlighting the approaches being investigated in this space. These include a monoclonal antibody, which has shown promising results thus far, as well as a bispecific antibody, vaccination against CALR, and a CALR-targeted CAR T-cell therapy. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think that this is one of the most important questions for the future because ET patients and the MF patients may be CALR-mutated in 20 to 30 percent of the cases and this mutation determines a neoantigen and this may be the target of specific treatment, immune specific treatment. And so we have now in the development of monoclonal antibody again against calreticulin and we presented data at the last EHA meeting in essential thrombocythemia...
I think that this is one of the most important questions for the future because ET patients and the MF patients may be CALR-mutated in 20 to 30 percent of the cases and this mutation determines a neoantigen and this may be the target of specific treatment, immune specific treatment. And so we have now in the development of monoclonal antibody again against calreticulin and we presented data at the last EHA meeting in essential thrombocythemia. Most of the patients responded in terms of reduction of the platelet and many patients responded in terms of reduction of the clone, and this is quite positive. Then we are also in development a bispecific against CD3 and CALR and we have not yet clinical results in this field. There is also experience with the vaccination against CALR that for the time being is not so active. And finally, there is also an in vitro study and preclinical study with CAR-T against CALR. But we have to wait, collect data and see what happens in the long term with these new treatments. That seems to be quite promising.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
